Barclays assumed coverage of Exelixis (EXEL) with an Equal Weight rating and $40 price target The firm expects the company’s main value drive, cabozantinib sales, to continue to grow mid-single digits to patent expiry in 2029, which is inline with consensus.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EXEL:
- Exelixis initiated with an Equal Weight at Barclays
- Exelixis Advances Phase 1 Study of XL309 for Advanced Solid Tumors
- Exelixis Advances in Neuroendocrine Tumor Treatment with New Clinical Trial
- Exelixis’s Promising Growth Potential and Strategic Expansion Justify Buy Rating
- Exelixis Announces New Executive VP for R&D